NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor

Inflammopharmacology

Volumn 12, Issue 5-6, 2005, Pages 521-534

  Ellis, James L ^a   Augustyniak, Michael E ^a   Cochran, Edward D ^a   Earl, Richard A ^a   Garvey, David S ^a   Gordon, Laura J ^a   Janero, David R ^a   Khanapure, Subhash P ^a   Letts, L Gordon ^a   Melim, Terry L ^a   Murty, Madhavi G ^a   Schwalb, David J ^a   Shumway, Matthew J ^a   Selig, William M ^a   Trocha, A Mark ^a   Young, Delano V ^a   Zemtseva, Irina S ^a  

^a NitroMed Inc   (United States)

Author keywords

Anti inflammatory; CINOD; Cyclo oxygenase; Gastric damage; Gastro protection; Naproxen; Nitric oxide; Non steroidal anti inflammatory drug (NSAID)

Indexed keywords

ANTIINFLAMMATORY AGENT; CARRAGEENAN; NAPROXEN; NAPROXEN DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRONAPROXEN; NMI 1182; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HUMAN; LEUKOCYTE; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; STOMACH LESION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA, ABDOMINAL; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; GASTRIC MUCOSA; HUMANS; INFLAMMATION; MALE; MOLECULAR STRUCTURE; NAPHTHALENES; NAPROXEN; NEUTROPHIL INFILTRATION; NITRIC OXIDE DONORS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 27744474179     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774382661     Document Type: Article

References (34)

1. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K. and Schnitzer, T. J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, N. Engl. J. Med. 343, 1520-1528.
2. Brown, J. F., Hanson, P. J. and Whittle, B. J. R. (1992). Nitric oxide donors increase mucus gel thickness in rat stomach, Eur. J. Pharmacol. 223, 101-104.
3. Brown, J. F., Keates, A. C., Hanson, P. J. and Whittle, B. J. R. (1993). Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells, Am. J. Physiol. 265, G418-G422.
4. Brune, K. and Hinz, B. (2004). Selective cyclooxygenase-2 inhibitors: similarities and differences, Scand. J. Rheumatol. 33, 1-6.
5. Couzin, J. (2004). Clinical trials. Halt of Celebrex study threatens drug's future, other trials, Science 306, 2170.
6. De Leval, X., Julemont, F., Benoit, V., Frederich, M., Pirotte, B. and Dogne, J. M. (2004). First and second generations of COX-2 selective inhibitors, Minirev. Med. Chem. 4, 597-601.
7. FDA (2005). FDA Statement, accessible at http://www.fda.gov/bbs/topics/ news/2005/NEW01151. html
8. Fiorucci, S., Santucci, L., Wallace, J. L., Sardina, M., Romano, M., Del Soldato, P. and Morelli, A. (2003). Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa, Proc. Natl. Acad. Sci. USA 100, 10937-10941.
9. Flower, R. J. (2003). The development of COX2 inhibitors, Nature Rev. Drug. Discov. 2, 179-191.
10. Hawkey, C. J., Jones, J. I., Atherton, C. T., Skelly, M. M., Bebb, J. R., Fagerholm, U., Jonzon, B., Karlsson, P. and Bjarnason, I. T. (2003). Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans, Gut 52, 1537-1542.
11. James, M. W. and Hawkey, C. J. (2003). Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract, Br. J. Clin. Pharmacol. 56, 146-155.
12. Janero, D. R., Cochran, E., Fang, X., Garvey, D. S., Letts, L. G., Marek, P. and Schroeder, J. (2002). Nitric oxide donor addition renders cyclooxygenase-2 (COX-2) selective inhibitors anti-thrombotic in vivo, Gut 51 (Suppl. III), A18.
13. Kubes, P., Suzuki, M. and Granger, D. N. (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion, Proc. Natl. Acad. Sci. USA 88, 4651-4655.
14. Kwiecien, S., Brzozowski, T., Konturek, P. C. and Konturek, S. J. (2002). The role of reactive oxygen species in action of nitric oxide-donors on stress-induced gastric mucosal lesions, J. Physiol. Pharmacol. 53, 761-773.
15. Laine, L., Maller, E. S., Yu, C., Quan, H. and Simon, T. (2004). Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial, Gastroenterology 127, 395-402.
16. Lisse, J. R., Perlman, M., Johansson, G., Shoemaker, J. R., Schechtman, J., Skalky, C. S., Dixon, M. E., Polis, A. B., Mollen, A. J. and Geba, G. P. for the ADVANTAGE Study Group (2003). Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial, Ann. Intern. Med. 139, 539-546.
17. Lohmander, L., McKeith, D., Svensson, O., Malmenäs, M., Bolin, L., Kalla, A., Genti, G., Szechinski, J. and Ramos-Remus, C. (2005). A randomised placebo-controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis, Ann. Rheum. Dis. 64, 449-456.
18. Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C. and Seibert, K. (1994). Selective inhibition of inducible cyclooxygenase 2 in vivo is and inflammatory and nonulcerogenic, Proc. Natl. Acad. Sci. USA 91, 3228-3232.
19. Mitchell, J. A. and Warner, T. D. (1999). Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy, Br. J. Pharmacol. 128, 1121-1132.
20. Mukherjee, D., Nissen, S. E. and Topol, E. J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors, J. Am. Med. Ass. 286, 954-959.
21. Muscara, M. N., McKnight, W., Del Soldato, P. and Wallace, J. L. (1998). Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat, Life Sci. 62, PL235-PL240.
22. Muscara, M. N., Lovren, F., McKnight, W., Dicay, M., Del Soldato, P., Triggle, C. R. and Wallace, J. L. (2001). Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats, Br. J. Pharmacol. 133, 1314-1322.
23. Ott, E., Nussmeier, N. A., Duke, P. C., Feneck, R. O., Alston, R. P., Snabes, M. C., Hubbard, R. C., Hsu, P. H., Saidman, L. J. and Mangano, D. T.; Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators (2003). Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery, J. Thorac. Cardiovasc. Surg. 125, 1481-1492.
24. Ranatunge, R. R., Augustyniak, M., Bandarage, U. K., Earl, R. A., Ellis, J. L., Garvey, D. S., Janero, D. R., Letts, L. G., Martino, A. M., Murty, M. G., Richardson, S. K., Schroeder, J. D., Shumway, M. J., Tam, S. W., Trocha, A. M. and Young, D. V. (2004). Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles, J. Med. Chem. 47, 2180-2193.
25. Reicin, A. S., Shapiro, D. and Sperling, R. S. (2002). Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone), Am. J. Cardiol. 89, 204-209.
26. Rossoni, G., Manfredi, B., Del Soldato, P. and Berti, F. (2004). The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion, J. Pharmacol. Exp. Ther. 310, 555-562.
27. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M. and Geis, G. S. (2000). Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study, J. Am. Med. Ass. 284, 1247-1255.
28. Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H. and Avorn, J. (2004). Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults, Circulation 109, 2068-2073.
29. Tramer, M. R., Moore, R. A., Reynolds, D. J. and McQuay, H. J. (2000). Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use, Pain 85, 169-182.
30. Vane, J. R., Bakhle, Y. S. and Botting, R. M. (1998). Cyclooxygenases 1 and 2, Annu. Rev. Pharmacol. Toxicol. 38, 97-120.
31. Walford, G. and Loscalzo, J. (2003). Nitric oxide in vascular biology, J. Thromb. Haemost. 1, 2112-2118.
32. Wallace, J. L., Chapman, K. and McKnight, W. (1999). Limited anti-inflammatory efficacy of cyclooxygenase-2 inhibition in carrageenan-airpouch inflammation, Br. J. Pharmacol. 126, 1200-1204.
33. Winter, C. A., Risley, E. A. and Nuss, G. W. (1962). Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs, Proc. Soc. Exp. Biol. Med. 111, 544-547.
34. Wolfe, M. M., Lichtenstein, D. R. and Singh, G. (1999). Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, N. Engl. J. Med. 340, 1888-1899.